Seagen Inc (SGEN)

202.88 -0.14 (-0.07%)
Real-time Cboe USD Disclaimer

Seagen Inc Company Profile

Sector
Healthcare
Employees
2675
Equity Type
ORD
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.
Contact Information
Address
Bothell,98021 United States
Phone
425 527 4000
Fax
-
Top Executives
Name
Age
Since
Title
Alpna H. Seth 59 2018 Independent Director
David W. Gryska 67 2005 Independent Director
Daniel G. Welch 64 2007 Independent Director
Nancy A. Simonian 61 2012 Independent Director
John A. Orwin 57 2014 Independent Director
Felix James Baker 53 2003 Lead Independent Director
Ted W. Love 63 2020 Independent Director
Sandra M. Swain 0 2022 Director
David R. Epstein 60 2022 CEO & Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles